ALECTOR INC (ALEC) Fundamental Analysis & Valuation

NASDAQ:ALEC • US0144421072

2.23 USD
-0.09 (-3.88%)
At close: Mar 12, 2026
2.21 USD
-0.02 (-0.9%)
After Hours: 3/12/2026, 4:30:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ALEC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall ALEC gets a fundamental rating of 2 out of 10. We evaluated ALEC against 519 industry peers in the Biotechnology industry. ALEC may be in some trouble as it scores bad on both profitability and health. ALEC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. ALEC Profitability Analysis

1.1 Basic Checks

  • In the past year ALEC has reported negative net income.
  • In the past year ALEC has reported a negative cash flow from operations.
  • In the past 5 years ALEC always reported negative net income.
  • In the past 5 years ALEC reported 4 times negative operating cash flow.
ALEC Yearly Net Income VS EBIT VS OCF VS FCFALEC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

1.2 Ratios

  • The Return On Assets of ALEC (-48.74%) is comparable to the rest of the industry.
  • ALEC has a worse Return On Equity (-466.34%) than 75.53% of its industry peers.
Industry RankSector Rank
ROA -48.74%
ROE -466.34%
ROIC N/A
ROA(3y)-31.71%
ROA(5y)-23.3%
ROE(3y)-219.14%
ROE(5y)-146.33%
ROIC(3y)N/A
ROIC(5y)N/A
ALEC Yearly ROA, ROE, ROICALEC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALEC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALEC Yearly Profit, Operating, Gross MarginsALEC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ALEC Health Analysis

2.1 Basic Checks

  • ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALEC has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALEC has more shares outstanding
  • ALEC has a worse debt/assets ratio than last year.
ALEC Yearly Shares OutstandingALEC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ALEC Yearly Total Debt VS Total AssetsALEC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -4.93, we must say that ALEC is in the distress zone and has some risk of bankruptcy.
  • ALEC has a worse Altman-Z score (-4.93) than 63.58% of its industry peers.
  • ALEC has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ALEC (0.32) is worse than 67.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z -4.93
ROIC/WACCN/A
WACC8.74%
ALEC Yearly LT Debt VS Equity VS FCFALEC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • ALEC has a Current Ratio of 3.83. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
  • ALEC has a Current ratio (3.83) which is in line with its industry peers.
  • A Quick Ratio of 3.83 indicates that ALEC has no problem at all paying its short term obligations.
  • The Quick ratio of ALEC (3.83) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.83
ALEC Yearly Current Assets VS Current LiabilitesALEC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ALEC Growth Analysis

3.1 Past

  • The earnings per share for ALEC have decreased strongly by -13.01% in the last year.
  • ALEC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -79.07%.
  • The Revenue has been decreasing by -0.05% on average over the past years.
EPS 1Y (TTM)-13.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1600%
Revenue 1Y (TTM)-79.07%
Revenue growth 3Y-45.99%
Revenue growth 5Y-0.05%
Sales Q2Q%-88.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.50% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 25.58% on average over the next years. This is a very strong growth
EPS Next Y16.97%
EPS Next 2Y15.69%
EPS Next 3Y6.74%
EPS Next 5Y9.5%
Revenue Next Year13.71%
Revenue Next 2Y28.51%
Revenue Next 3Y8.29%
Revenue Next 5Y25.58%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALEC Yearly Revenue VS EstimatesALEC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M
ALEC Yearly EPS VS EstimatesALEC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALEC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALEC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALEC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALEC Price Earnings VS Forward Price EarningsALEC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEC Per share dataALEC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.69%
EPS Next 3Y6.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALEC Dividend Analysis

5.1 Amount

  • No dividends for ALEC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALEC Fundamentals: All Metrics, Ratios and Statistics

ALECTOR INC

NASDAQ:ALEC (3/12/2026, 4:30:01 PM)

After market: 2.21 -0.02 (-0.9%)

2.23

-0.09 (-3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners77.65%
Inst Owner Change22.97%
Ins Owners6.6%
Ins Owner Change-0.58%
Market Cap246.10M
Revenue(TTM)21.05M
Net Income(TTM)-142.93M
Analysts50.77
Price Target2.14 (-4.04%)
Short Float %6.22%
Short Ratio6.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.67%
Min EPS beat(2)13.14%
Max EPS beat(2)18.2%
EPS beat(4)4
Avg EPS beat(4)21.13%
Min EPS beat(4)13.14%
Max EPS beat(4)36.06%
EPS beat(8)8
Avg EPS beat(8)31.35%
EPS beat(12)12
Avg EPS beat(12)36.73%
EPS beat(16)13
Avg EPS beat(16)19.9%
Revenue beat(2)2
Avg Revenue beat(2)67.32%
Min Revenue beat(2)5.84%
Max Revenue beat(2)128.8%
Revenue beat(4)3
Avg Revenue beat(4)74.41%
Min Revenue beat(4)-17.7%
Max Revenue beat(4)180.71%
Revenue beat(8)6
Avg Revenue beat(8)65.17%
Revenue beat(12)9
Avg Revenue beat(12)138.95%
Revenue beat(16)10
Avg Revenue beat(16)102.89%
PT rev (1m)0%
PT rev (3m)2.44%
EPS NQ rev (1m)12.72%
EPS NQ rev (3m)11.79%
EPS NY rev (1m)8.33%
EPS NY rev (3m)3.84%
Revenue NQ rev (1m)101.99%
Revenue NQ rev (3m)303.99%
Revenue NY rev (1m)12.64%
Revenue NY rev (3m)-55.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.69
P/FCF N/A
P/OCF N/A
P/B 8.03
P/tB 8.03
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0.19
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.74%
ROE -466.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.71%
ROA(5y)-23.3%
ROE(3y)-219.14%
ROE(5y)-146.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.72%
Cap/Sales 0.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.83
Quick Ratio 3.83
Altman-Z -4.93
F-Score1
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)21.84%
Cap/Depr(5y)37.65%
Cap/Sales(3y)1.3%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1600%
EPS Next Y16.97%
EPS Next 2Y15.69%
EPS Next 3Y6.74%
EPS Next 5Y9.5%
Revenue 1Y (TTM)-79.07%
Revenue growth 3Y-45.99%
Revenue growth 5Y-0.05%
Sales Q2Q%-88.5%
Revenue Next Year13.71%
Revenue Next 2Y28.51%
Revenue Next 3Y8.29%
Revenue Next 5Y25.58%
EBIT growth 1Y-9.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.93%
EBIT Next 3Y-6.35%
EBIT Next 5Y19.78%
FCF growth 1Y20.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.95%
OCF growth 3YN/A
OCF growth 5YN/A

ALECTOR INC / ALEC FAQ

What is the ChartMill fundamental rating of ALECTOR INC (ALEC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALEC.


What is the valuation status of ALECTOR INC (ALEC) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALECTOR INC (ALEC). This can be considered as Overvalued.


Can you provide the profitability details for ALECTOR INC?

ALECTOR INC (ALEC) has a profitability rating of 0 / 10.


How financially healthy is ALECTOR INC?

The financial health rating of ALECTOR INC (ALEC) is 3 / 10.